Literature DB >> 15951814

A critical function for type I interferons in cancer immunoediting.

Gavin P Dunn1, Allen T Bruce, Kathleen C F Sheehan, Vijay Shankaran, Ravindra Uppaluri, Jack D Bui, Mark S Diamond, Catherine M Koebel, Cora Arthur, J Michael White, Robert D Schreiber.   

Abstract

'Cancer immunoediting' is a process wherein the immune system protects hosts against tumor development and facilitates outgrowth of tumors with reduced immunogenicity. Although interferon-gamma (IFN-gamma) is known to be involved in this process, the involvement of type I interferons (IFN-alpha/beta) has not been elucidated. We now show that, like IFN-gamma, endogenously produced IFN-alpha/beta was required for the prevention of the growth of primary carcinogen-induced and transplantable tumors. Although tumor cells are important IFN-gamma targets, they are not functionally relevant sites of the actions of the type I interferons. Instead, host hematopoietic cells are critical IFN-alpha/beta targets during development of protective antitumor responses. Therefore, type I interferons are important components of the cancer immunoediting process and function in a way that does not completely overlap the functions of IFN-gamma.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15951814     DOI: 10.1038/ni1213

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  224 in total

1.  Type I interferon signals control Theiler's virus infection site, cellular infiltration and T cell stimulation in the CNS.

Authors:  Young-Hee Jin; Wanqiu Hou; Seung Jae Kim; Alyson C Fuller; Bongsu Kang; Gwen Goings; Stephen D Miller; Byung S Kim
Journal:  J Neuroimmunol       Date:  2010-06-09       Impact factor: 3.478

2.  Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.

Authors:  Arnold I Chin; Andrea K Miyahira; Anthony Covarrubias; Juli Teague; Beichu Guo; Paul W Dempsey; Genhong Cheng
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

Review 3.  Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer.

Authors:  Leticia Corrales; Thomas F Gajewski
Journal:  Clin Cancer Res       Date:  2015-09-15       Impact factor: 12.531

Review 4.  Type-I-interferons in infection and cancer: Unanticipated dynamics with therapeutic implications.

Authors:  Martina Musella; Gwenola Manic; Ruggero De Maria; Ilio Vitale; Antonella Sistigu
Journal:  Oncoimmunology       Date:  2017-04-05       Impact factor: 8.110

5.  ISG15 Arg151 and the ISG15-conjugating enzyme UbE1L are important for innate immune control of Sindbis virus.

Authors:  Nadia V Giannakopoulos; Elena Arutyunova; Caroline Lai; Deborah J Lenschow; Arthur L Haas; Herbert Whiting Virgin
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

6.  A safe and highly efficient tumor-targeted type I interferon immunotherapy depends on the tumor microenvironment.

Authors:  Anje Cauwels; Sandra Van Lint; Geneviève Garcin; Jennyfer Bultinck; Franciane Paul; Sarah Gerlo; José Van der Heyden; Yann Bordat; Dominiek Catteeuw; Lode De Cauwer; Elke Rogge; Annick Verhee; Gilles Uzé; Jan Tavernier
Journal:  Oncoimmunology       Date:  2017-11-27       Impact factor: 8.110

7.  IFNAR1 Controls Autocrine Type I IFN Regulation of PD-L1 Expression in Myeloid-Derived Suppressor Cells.

Authors:  Wei Xiao; John D Klement; Chunwan Lu; Mohammed L Ibrahim; Kebin Liu
Journal:  J Immunol       Date:  2018-05-11       Impact factor: 5.422

8.  E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs.

Authors:  Enguang Bi; Rong Li; Laura C Bover; Haiyan Li; Pan Su; Xingzhe Ma; Chunjian Huang; Qiang Wang; Lintao Liu; Maojie Yang; Zhijuan Lin; Jianfei Qian; Weijun Fu; Yong-Jun Liu; Qing Yi
Journal:  J Clin Invest       Date:  2018-10-02       Impact factor: 14.808

Review 9.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

Review 10.  Immune surveillance of tumors.

Authors:  Jeremy B Swann; Mark J Smyth
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.